Medicinova (MNOV) 3.96 $MNOV MediciNova Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medicinova (MNOV) 3.96 $MNOV

MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS
GlobeNewswire - Tue Apr 21, 12:45PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigator, presented interim safety data from the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. There were no safety or tolerability concerns in the MN-166 (ibudilast) treatment group compared with the placebo treatment group after three months of treatment.
MNOV: 3.96 (-0.12)

How Energetic is Healthcare and How Healthy is The Energy Sector: Free Research on MediciNova, Cardica, Rosetta Genomics, Gulf Port Energy, Matador Resources
PR Newswire - Tue Apr 21, 9:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ROSG: 3.83 (-0.20), MNOV: 3.96 (-0.12), CRDC: 0.44 (+0.01), MTDR: 26.96 (+0.53), GPOR: 49.00 (-0.49)

MediciNova Gets Fast Tracked Into Thick Of NASH Race
Clinically Sound Investor - at Seeking Alpha - Thu Apr 16, 3:29PM CDT

MNOV: 3.96 (-0.12)

MedicNova (MNOV) Stock is Gaining Today After Drug Receives Fast Track Designation
at The Street - Thu Apr 16, 1:21PM CDT
MedicNova (MNOV) shares are climbing after its drug received fast track status from the Food and Drug Administration.
MNOV: 3.96 (-0.12)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:45AM CDT

NPD: 2.87 (+0.25), INVE: 10.16 (-0.48), MNOV: 3.96 (-0.12), NHTC: 21.52 (+1.57), BSPM: 1.45 (-0.05), ANY: 3.33 (-0.16), TZOO: 13.06 (-0.02), FNRG: 3.11 (-0.86), RLJE: 1.06 (-0.01), PRTY: 20.65 (-0.22), PTX: 7.44 (-0.05), RCPI: 3.05 (+0.03), CHOP: 3.67 (-0.26), NVGN: 7.40 (-0.30), ETSY: 25.12 (-0.63), NFLX: 557.68 (-2.76), ENZN: 1.70 (+0.20), INUV: 2.32 (-0.05), GLF: 13.77 (-0.11), PCRX: 83.61 (-0.41)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:12AM CDT

NFLX: 557.68 (-2.76), PM: 83.69 (-0.36), INVE: 10.16 (-0.48), SNTA: 2.97 (+0.01), MNOV: 3.96 (-0.12), TZOO: 13.06 (-0.02), PNRA: 181.59 (-2.26), CLRX: 0.95 (unch), REN: 1.36 (-0.06), PTX: 7.44 (-0.05), CPLP: 9.48 (-0.17), NVGN: 7.40 (-0.30), MTDR: 26.96 (+0.53), PCRX: 83.61 (-0.41), SNDK: 68.48 (+0.56)

MediciNova up 42% premarket on Fast Track status for NASH candidate
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:05AM CDT

MNOV: 3.96 (-0.12)

Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan
GlobeNewswire - Thu Apr 16, 7:30AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that the Tokyo Stock Exchange (TSE) has announced a new rule affecting the trading of dual-listed stocks on the Tokyo Stock Exchange, including the stock of MediciNova. Under the old rule, the TSE had used the previous day's closing price of MediciNova's stock on the TSE as the base price to determine the daily limit of the stock price movement on the TSE (also known as the "circuit breaker" rule). Under the new rule that will become effective on April 20, 2015, if (1) the difference between the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen and the previous day's closing price of MediciNova's stock on the TSE ("the price divergence" is greater than the daily limit of the stock price movement on the TSE and (2) the price divergence is greater than 20%, then the TSE will use the previous day's closing price of MediciNova's stock on NASDAQ converted to Japanese yen as the base price to determine the daily limit of the stock price movement on the TSE.
MNOV: 3.96 (-0.12)

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis
GlobeNewswire - Thu Apr 16, 7:05AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-001 (tipelukast) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 3.96 (-0.12)

MediciNova reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 7:05AM CDT

MNOV: 3.96 (-0.12)

MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona
GlobeNewswire - Mon Mar 02, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova's ongoing Phase 2a clinical trial of MN-166 (ibudilast) in opioid dependence has been selected for presentation at the 77 Annual Meeting of the College on Problems of Drug Dependence (CPDD) to be held June 13-18, 2015 in Phoenix, Arizona. The results will be presented by Dr. Verena Metz of the New York State Psychiatric Hospital (NYSPI) at Columbia University.
MNOV: 3.96 (-0.12)

MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS
GlobeNewswire - Mon Feb 16, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has enrolled 30 of the 60 subjects planned for participation.
MNOV: 3.96 (-0.12)

MediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF
GlobeNewswire - Tue Feb 10, 8:07AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that FDA (U.S. Food and Drug Administration) has approved the protocol for a clinical trial of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis). Importantly, due to safety data from previous clinical studies of MN-001, FDA has agreed that MediciNova may proceed with a Phase 2 study as the first clinical trial of MN-001 in IPF. The IPF protocol was filed under MediciNova's open IND (Investigational New Drug Application) in FDA's Division of Pulmonary, Allergy, and Rheumatology Products (DPARP). FDA has granted orphan-drug designation to MN-001 for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if MN-001 is approved for IPF.
MNOV: 3.96 (-0.12)

MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office
M2 - Wed Feb 04, 5:23AM CST
Biopharmaceutical company
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 32

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 89

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 73

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 40

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 18

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 192

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 62

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 74

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading

Top 5 Most Recently Viewed Articles

Legit Security Named as a Top Performer in Application Security

Updated Category News Views 210

Legit Security Recognized as a Leader in Application Security Legit Security, a leader in AI-native Application Security Posture Management (ASPM), has recently been acknowledged as a prominent player in the IDC MarketScape for ASPM. This achievement reflects the company's commitment to securing AI-powered application development processes. The IDC MarketScape report...

Continue Reading
Active Dental Transforms Patient Experience with New Website

Updated Category News Views 140

Active Dental Enhances Patient Accessibility with Unified Website Active Dental, a reputable family and general dentistry practice in the Dallas-Fort Worth metroplex, has launched a newly redesigned website that seamlessly integrates all five of its practice locations into a single, user-friendly digital platform. This significant upgrade aims to make appointment...

Continue Reading
Stork Club's Innovative Approach to Postpartum Depression Support

Updated Category News Views 229

Stork Club Innovates Reproductive Health Care Stork Club has recently launched an unprecedented initiative aimed at addressing postpartum depression (PPD) among working mothers. This pioneering program offers a seamless blend of digital diagnostics and therapy, leading to significant improvements in mental health outcomes. With up to 20% immediate relief from PPD symptoms...

Continue Reading
Investors Eye Class Action Against Fortrea Holdings, Inc.

Updated Category News Views 114

Understanding the Fortrea Holdings, Inc. Class Action Fortrea Holdings, Inc. (NASDAQ: FTRE) has gained attention due to rising investor concerns regarding its recent financial disclosures. Investors who have experienced losses over $100,000 are now presented with an opportunity to potentially lead a securities fraud lawsuit against the company. This lawsuit highlights...

Continue Reading
Alpha Tau Medical Plans Engagements at Key Healthcare Events

Updated Category News Views 91

Upcoming Participation in Major Healthcare Conferences Alpha Tau Medical Ltd., a leading developer of innovative cancer therapies, is gearing up for an exciting presence at significant healthcare conferences. The involvement of the Chief Financial Officer, Raphi Levy, at these events marks a pivotal opportunity for the company to showcase its groundbreaking...

Continue Reading